Gene/Protein
Disease
Symptom
Drug
Enzyme
Compound
Pivot Concepts:
Gene/Protein
Disease
Symptom
Drug
Enzyme
Compound
Target Concepts:
Gene/Protein
Disease
Symptom
Drug
Enzyme
Compound
Query: UMLS:C0019204 (
hepatocellular carcinoma
)
71,386
document(s) hit in 31,850,051 MEDLINE articles (0.00 seconds)
Chromodomain helicase DNA binding protein 5
(
CHD5
) acts as a tumor suppressor in many cancers. In the present study, we demonstrated that reduced levels of
CHD5
in
hepatocellular carcinoma
(
HCC
) tissues were significantly associated with metastasis and poor prognosis. Gain-of-function assays revealed that
CHD5
suppressed motility and invasion of
HCC
cells. Subsequent investigations showed that
CHD5
was epigenetically silenced by polycomb repressive complex 2 (PRC2)-mediated the trimethylation of histone H3 at lysine 27 (H3K27me3) in
HCC
cells. Furthermore, overexpression of
CHD5
repressed enhancer of zeste homolog 2 (EZH2) and activated PRC2 target genes, such as p16 and p21. Chromatin immunoprecipitation and luciferase reporter assays also showed that
CHD5
and EZH2 bind to each other's promoters and inhibit transcription. These findings uncovered, for the first time, a mutual suppression regulation between
CHD5
and EZH2, which may provide new insights into their potential therapeutic significance for
HCC
.
...
PMID:Mutual regulation between CHD5 and EZH2 in hepatocellular carcinoma. 2651 14